Decision Resources announced today the release of its new report focusing on drugs to help regulate cell death. Apoptosis, programmed cell death, can occur as a physiological or pathological process within the body. Abnormal regulation of apoptosis can play a role in a variety of diseases such as rheumatoid arthritis, Alzheimer's disease and cancer. The report found that apoptosis modulators have the potential to attain blockbuster status, earning at least $1 billion in sales per year.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

The report entitled Apoptosis Modulators: Emerging Therapeutic Applications found that the race to develop and market apoptosis modulators has already begun. In April 2002, Aventis agreed to pay up to $480 million for the rights to Genta's BCL-2 apoptosis-modulating antisense therapy. This agreement is the second largest deal recorded between a big pharmaceutical company and a biotechnology company for a single agent.

"In today's environment, pharmaceutical companies are looking to sustain themselves by bringing blockbuster drugs to market," said Carilee Berg, Ph.D., analyst at Decision Resources. "Based on our findings, it is clear that apoptosis modulators have the potential to achieve that status."

Apoptosis Modulators: Emerging Therapeutic Applications discusses the potential of emerging apoptosis-modulating therapies to address the unmet clinical needs of acute myocardial infarction, prostate cancer, rheumatoid arthritis, sepsis and Alzheimer's disease. Companies developing these agents are profiled. The report also discusses the impact that emerging apoptosis- modulating therapies will have on these disease markets.

About Pathways and Processes from Decision Resources

Apoptosis Modulators: Emerging Therapeutic Applications is the first report from Pathways and Processes, a new advisory service that focuses on cellular and molecular pathways. The reports provide insight into cutting-edge developments relating to drug targets that have the potential to significantly change treatment practice and impact multiple pharmaceutical markets.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.decisionresources.com/.

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresource.com 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X91658741

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresource.com

Decision Resources Publishes New Report on Obesity

View Now